Shanghai Institute of Biological Products' Shangsheng Influenza Vaccine Series Achieves Milestone

Strategic Insights -

The Shangsheng influenza vaccine series has achieved a significant milestone by becoming the first unified dosage form for people aged 6 months and above in China. This achievement follows the approval by the National Medical Products Administration of the supplementary application for the trivalent influenza virus split vaccine (0.5ml/dose) of China National Biotec Group Shanghai Institute of Biological Products, expanding its vaccination targets to include people aged 6-35 months. The Shanghai Sheng trivalent influenza virus split vaccine was first approved in China in 2000 and has been supplied to the market for over 20 years, benefiting more than 50 million people.

Key Takeaways:

  • The Shangsheng influenza vaccine series has achieved the first unified dosage form for people aged 6 months and above in China, with the 0.5ml/dose vaccine approved by the National Medical Products Administration for ages 6-35 months.
  • The Shangsheng quadrivalent influenza virus split vaccine was first approved in China in 2022, expanding its age range to include people 6 months and above.
  • The Shanghai Sheng trivalent influenza virus split vaccine has been supplied to the market for over 20 years, benefiting more than 50 million people.
  • The product has won honorary titles such as "National Key New Product", "Shanghai Pharmaceutical Industry Famous and Excellent Product", and "Shanghai Famous Brand Product".
  • The production implementation standard of the vaccine is better than the national pharmacopoeia, with a more stable pH value, lower free formaldehyde content, no thimerosal, and lower ovalbumin content.
  • The immunogenicity of the vaccine is higher than the international standard, and its safety has been observed to be good after it has been put on the market.
  • The dosage form for infants, adolescents, adults, and the elderly is unified.

Statistics:

  • Over 50 million people have benefited from the Shanghai Sheng trivalent influenza virus split vaccine over the past 20 years.
  • The vaccine has been approved by the National Medical Products Administration for ages 6-35 months.
  • The production standard of the vaccine is better than the national pharmacopoeia, with a more stable pH value (pH 6.5-7.5), lower free formaldehyde content (less than 1 ppm), no thimerosal, and lower ovalbumin content (less than 0.1 mg).

Sources:

  • Shanghai Institute of Biological Products Co., Ltd.
  • National Medical Products Administration (explicit date not provided)
  • Shanghai Pharmaceutical Industry Famous and Excellent Product (no date)
  • Shanghai Famous Brand Product (no date)
  • National Key New Product (no date)
  • Chinese Center for Disease Control and Prevention (no date)